268 related articles for article (PubMed ID: 25342375)
21. Rituximab in primary Sjögren's syndrome: a ten-year journey.
Carubbi F; Alunno A; Cipriani P; Bartoloni E; Ciccia F; Triolo G; Gerli R; Giacomelli R
Lupus; 2014 Nov; 23(13):1337-49. PubMed ID: 25096066
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Sjögren's syndrome: current therapy and future directions.
Fox RI; Fox CM; Gottenberg JE; Dörner T
Rheumatology (Oxford); 2021 May; 60(5):2066-2074. PubMed ID: 31034046
[TBL] [Abstract][Full Text] [Related]
23. Novel Therapeutic Strategies in Primary Sjögren's Syndrome.
Alunno A; Carubbi F; Bistoni O; Bartoloni E; Valentini V; Gerli R
Isr Med Assoc J; 2017 Sep; 19(9):576-580. PubMed ID: 28971643
[TBL] [Abstract][Full Text] [Related]
24. Biologic therapy in Sjögren's syndrome.
Shao Q
Clin Rheumatol; 2021 Jun; 40(6):2143-2154. PubMed ID: 33106929
[TBL] [Abstract][Full Text] [Related]
25. Treatment for salivary gland hypofunction at both initial and advanced stages of Sjögren-like disease: a comparative study of bone marrow therapy versus spleen cell therapy with a 1-year monitoring period.
Khalili S; Faustman DL; Liu Y; Sumita Y; Blank D; Peterson A; Kodama S; Tran SD
Cytotherapy; 2014 Mar; 16(3):412-23. PubMed ID: 24411591
[TBL] [Abstract][Full Text] [Related]
26. Rituximab therapy in primary Sjögren's syndrome.
Alcântara C; Gomes MJ; Ferreira C
Ann N Y Acad Sci; 2009 Sep; 1173():701-5. PubMed ID: 19758218
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial.
Meijer JM; Meiners PM; Vissink A; Spijkervet FK; Abdulahad W; Kamminga N; Brouwer E; Kallenberg CG; Bootsma H
Arthritis Rheum; 2010 Apr; 62(4):960-8. PubMed ID: 20131246
[TBL] [Abstract][Full Text] [Related]
28. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review.
Sumida T; Tsuboi H; Iizuka M; Hirota T; Asashima H; Matsumoto I
J Autoimmun; 2014 Jun; 51():44-50. PubMed ID: 24397962
[TBL] [Abstract][Full Text] [Related]
29. Transfer of Sjögren's syndrome-like autoimmune lesions into SCID mice and prevention of lesions by anti-CD4 and anti-T cell receptor antibody treatment.
Hayashi Y; Haneji N; Hamano H; Yanagi K
Eur J Immunol; 1994 Nov; 24(11):2826-31. PubMed ID: 7957574
[TBL] [Abstract][Full Text] [Related]
30. Biological therapies in primary Sjögren's syndrome.
Ng WF; Bowman SJ
Expert Opin Biol Ther; 2011 Jul; 11(7):921-36. PubMed ID: 21457124
[TBL] [Abstract][Full Text] [Related]
31. Treatment of the patient with Sjögren's syndrome.
Fox RI
Rheum Dis Clin North Am; 1992 Aug; 18(3):699-709. PubMed ID: 1496169
[TBL] [Abstract][Full Text] [Related]
32. Management of patients presenting with Sjogren's syndrome.
Venables PJ
Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):791-807. PubMed ID: 16979538
[TBL] [Abstract][Full Text] [Related]
33. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
34. The future of biologic agents in the treatment of Sjögren's syndrome.
Meijer JM; Pijpe J; Bootsma H; Vissink A; Kallenberg CG
Clin Rev Allergy Immunol; 2007 Jun; 32(3):292-7. PubMed ID: 17992596
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of Sjögren's syndrome and therapeutic consequences.
Mariette X; Gottenberg JE
Curr Opin Rheumatol; 2010 Sep; 22(5):471-7. PubMed ID: 20671520
[TBL] [Abstract][Full Text] [Related]
36. Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study).
Meiners PM; Vissink A; Kroese FG; Spijkervet FK; Smitt-Kamminga NS; Abdulahad WH; Bulthuis-Kuiper J; Brouwer E; Arends S; Bootsma H
Ann Rheum Dis; 2014 Jul; 73(7):1393-6. PubMed ID: 24473674
[TBL] [Abstract][Full Text] [Related]
37. Issues related to clinical trials of oral and biologic disease-modifying agents for Sjögren's syndrome.
Carsons SE
Rheum Dis Clin North Am; 2008 Nov; 34(4):1011-23, x. PubMed ID: 18984419
[TBL] [Abstract][Full Text] [Related]
38. [Sjögren's syndrome: therapeutic trends].
Di Giacinto G; Piergiacomi G
Clin Ter; 1991 Nov 15-30; 139(3-4):81-92. PubMed ID: 1837255
[TBL] [Abstract][Full Text] [Related]
39. Sjögren's syndrome.
Venables PJ
Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):313-29. PubMed ID: 15158743
[TBL] [Abstract][Full Text] [Related]
40. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome.
Pijpe J; Meijer JM; Bootsma H; van der Wal JE; Spijkervet FK; Kallenberg CG; Vissink A; Ihrler S
Arthritis Rheum; 2009 Nov; 60(11):3251-6. PubMed ID: 19877054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
